Abstract
Purpose: :
The objective of this study was to determine the intraocular pressure (IOP)–lowering efficacy over a twenty–four hour period of travoprost 0.004% ophthalmic solution (Travatan®, Alcon Laboratories Inc., Fort Worth, TX) compared to latanoprost 0.005% (Xalatan®, Pfizer Inc., New York, NY) dosed once–a–day in patients with primary open–angle glaucoma or ocular hypertension.
Methods: :
During the eligibility visit, IOP was measured every 4 hours throughout a 24–hour period. Sixty–two patients were randomized to receive either travoprost (n = 32) or latanoprost (n = 30) one drop at 8 PM daily for two weeks. IOP was measured at week 2 every 4 hours throughout two consecutive 24–hour periods. All measurements were taken with a Perkins applanation tonometer. For continuous, non–repeated, normally distributed data, a t–test was used.
Results: :
Travoprost produced lower mean IOP values than latanoprost at all time points which were significantly (P < 0.05) lower for travoprost at 12, 16, 20, 24, 36, 40 and 48 hours after the last dose. Mean IOP reductions from baseline ranged from 6 to 10 mmHg for travoprost and 4 to 8 mmHg for latanoprost. The mean circadian IOP (±SD) values for patients taking travoprost and latanoprost, respectively, were 16.8 ± 3.3 and 18.9 ± 3.3 mmHg during the first 24 hours; 18.1 ± 3.4 and 20.7 ± 3.3 mmHg during the last 24 hours; and 17.5 ± 3.3 and 19.8 ± 3.2 mmHg throughout the entire week 2 visit (P < 0.05). Travoprost and latanoprost were both safe and well tolerated.
Conclusions: :
The results of the study demonstrate that travoprost 0.004% ophthalmic solution has a longer duration and superior ocular hypotensive efficacy after cessation of topical administration than does latanoprost 0.005%.
Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure